SCHEMBL464847

SCHEMBL464847

O=C(Cl)c1ccccc1SCl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
ALOX15 P16050 2/20 0.50
POLB P06746 4/20 0.45
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CYP1A2 P05177 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
CES2 O00748 2/20 0.38
CES1 P23141 2/20 0.38
RAB9A P51151 2/20 0.35
NR4A1 P22736 1/20 0.34
NR4A2 P43354 1/20 0.34
NR4A3 Q92570 1/20 0.34
TSHR P16473 1/20 0.34
PKM P14618 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30655797 1.00 ALDH1A1 (0.50) ALDH1A1ALOX15POLBCA12CA1
SCHEMBL823696 0.84 POLB (0.64) ALDH1A1ALOX15POLBCA12CA1
SCHEMBL29378135 0.84 POLB (0.64) ALDH1A1ALOX15POLBCA12CA1
SCHEMBL9815789 0.84 ALDH1A1 (0.52) ALDH1A1ALOX15POLBCA12CA1
SCHEMBL16534454 0.82 POLB (0.68) ALDH1A1ALOX15POLBCA12CA1
SCHEMBL3440670 0.80 HTT (0.51) ALDH1A1ALOX15RAB9ATSHRNPC1
SCHEMBL7418361 0.80 SIRT1 (0.60) ALDH1A1POLBSIRT1RAB9ATSHR
SCHEMBL422 0.77 ALDH1A1 (0.67) ALDH1A1ALOX15POLBCA12CA1
SCHEMBL11476180 0.77 SIRT1 (0.67) ALDH1A1ALOX15POLBCA12CA1
SCHEMBL7189083 0.75 ALDH1A1 (0.48) ALDH1A1ALOX15POLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861162-A Preparation process of photoinitiator 2-/4-isopropyl thioxanthone 喆鹿(山东)新材料有限公司 2021-12-31 CN claimed
US-4101558-A Process for preparing thioxanthones THE SHERWIN-WILLIAMS COMPANY (US) 1978-07-18 US claimed
CN-116964043-A Type II photoinitiators 阿科玛法国公司 2023-10-27 CN disclosed
CN-113861162-A Preparation process of photoinitiator 2-/4-isopropyl thioxanthone 喆鹿(山东)新材料有限公司 2021-12-31 CN disclosed
CN-113861162-A Preparation process of photoinitiator 2-/4-isopropyl thioxanthone 喆鹿(山东)新材料有限公司 2021-12-31 CN disclosed
CN-107663182-B Glutamine metabolism inhibitor compound 杭州健昵福生物科技有限公司 2020-12-22 CN disclosed
US-10711002-B2 Purine compounds and method for the treatment of cancer THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2020-07-14 US disclosed
US-20190119279-A1 PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-04-25 US disclosed
WO-2017181285-A1 PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-10-26 WO disclosed
US-9694086-B2 HCV protease inhibitors and uses thereof CELGENE CAR LLC (BM) 2017-07-04 US disclosed
US-20160243249-A1 HCV PROTEASE INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2016-08-25 US disclosed
US-5348946-A Heteroanthracycline antitumor analogs BIOCHEM IMMUNOSYSTEMS, INC. (CA) 1994-09-20 US disclosed
WO-1994020479-A1 N-(BETA-BRANCHED ALKYL)-1,2-BENZISOTHIAZOLIN-3-ONES, THEIR PREPARATION AND USE AS INDUSTRIAL BIOCIDES ZENECA LIMITED (GB) 1994-09-15 WO disclosed
EP-0502661-A2 Heteroanthracycline anti-tumor analogues BIOCHEM PHARMA INC. (CA) 1992-09-09 EP disclosed
EP-0269339-A2 Novel daunomycin and adriamycin sulfono and sulfoxo ABI BIOTECHNOLOGY INC. (CA) 1988-06-01 EP disclosed
EP-0141119-A2 Sulfenamide derivatives, process for their preparation, and medicaments containing these compounds LUDWIG HEUMANN & CO GMBH (DE) 1985-05-15 EP disclosed
US-4399145-A Lactams Compositions and pharmaceutical methods of use GRUNENTHAL GMBH (DE) 1983-08-16 US disclosed
EP-0054672-A1 Lactam compounds, pharmaceutical preparations containing them, and processes for the preparation of these compounds and pharmaceutical preparations Grünenthal GmbH (DE) 1982-06-30 EP disclosed
US-4101558-A Process for preparing thioxanthones THE SHERWIN-WILLIAMS COMPANY (US) 1978-07-18 US disclosed
US-4101558-A Process for preparing thioxanthones THE SHERWIN-WILLIAMS COMPANY (US) 1978-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711002-B2 Purine compounds and method for the treatment of cancer PNP, NUDT1, HPRT1 ALDH1A1 236/4885ALOX15 2322/4885POLB 306/4885
US-20160243249-A1 HCV PROTEASE INHIBITORS AND USES THEREOF PEPD, CTRL, CTSC ALDH1A1 1344/4885ALOX15 1685/4885POLB 3055/4885
US-20190119279-A1 PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER PNP, NUDT1, HPRT1 ALDH1A1 236/4885ALOX15 2322/4885POLB 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.